CELG up +1.34% percent Today $CELG High is at 105.49 and

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
CELG up +1.34% percent Today $CELG High is at 105.49 and the Low 103.26 with current volume of 667,845.

Recent News posted below.

Celgene Corp CELG other info.
http://investorshangout.com/Celgene-Corporation-CELG-53644/

CELG Celgene Corp Recent Headline News

Early Glance: Biotechnology companies
AP - 48 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 101.07 (-0.99), AMGN: 159.34 (+1.66), CELG: 105.00 (+0.95)

Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases
Business Wire - 2 hrs 16 mins ago
In a major step to treat patients living with Myelodysplastic Syndromes (MDS), a group of diseases that affect the bone marrow and blood, Moffitt Cancer Center today announced the development of an innovative investigational biologic agent that could improve patient response and outcomes for MDS and other diseases.
CELG: 105.00 (+0.95), CELGZ: 3.29 (+0.01)

Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015
George Budwell, The Motley Fool - Motley Fool - Mon Nov 17, 7:13AM CST
As the healthcare sector rolls through its third-quarter earnings, a bucolic picture is coming into focus. Earnings across the sector are soaring due to new drug launches, a frenzy of acquisitions, and vast reorganizations that have helped to stem...
JNJ: 108.29 (+0.13), GILD: 101.07 (-0.99), ABBV: 65.18 (+1.18), CELG: 105.00 (+0.95)

'Fast Money' Recap: Was Friday the Start of a Bull Rally in Gold?
at The Street - Sat Nov 15, 4:00AM CST
The trading panel took a look at gold prices, which climbed 2.3% on Friday, as well as the potential for a pullback in biotech stocks.
AMZN: 320.27 (-7.55), TSRO: 30.43 (+0.81), XBI: 170.32 (+2.40), IBB: 291.26 (+3.09), CELG: 105.00 (+0.95), GILD: 101.07 (-0.99), GLD: 113.88 (-0.59), MCD: 95.85 (-0.36), SLV: 15.43 (-0.20), GDX: 19.06 (+0.04), TWTR: 40.94 (-0.91), AAPL: 114.24 (+0.06), BABA: 114.60 (-0.50)

Medical Stocks Tumble But Most Of IBD 50 Trading Well
at Investor's Business Daily - Fri Nov 14, 5:47PM CST
A few medical leading stocks have slid, but otherwise the IBD 50 remained in good shape last week. Illumina (ILMN) and Akorn (AKRX) have fallen below their buy points, while Alexion Pharmaceuticals (ALXN) and Celgene (CELG) exhibited some weakness of...
AKRX: 38.94 (+0.73), ALXN: 189.14 (+0.38), FFIV: 127.45 (-1.43), ILMN: 182.21 (+1.71), SPR: 41.12 (-0.08), AAPL: 114.24 (+0.06), ATHM: 43.17 (-1.41), BITA: 89.00 (-2.91), CELG: 105.00 (+0.95)

Final Glance: Biotechnology companies
AP - Fri Nov 14, 5:03PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 101.07 (-0.99), AMGN: 159.34 (+1.66), CELG: 105.00 (+0.95)

Look for Shares of Celgene to Potentially Rebound after Yesterday's 3.15% Sell Off
Comtex SmarTrend(R) - Fri Nov 14, 3:41PM CST
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $102.13 to a high of $107.65. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $106.54 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 105.00 (+0.95)

Watch for Celgene to Potentially Rebound After Falling 3.15% Yesterday
Comtex SmarTrend(R) - Fri Nov 14, 3:41PM CST
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $102.13 to a high of $107.65. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $106.54 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 105.00 (+0.95)

Stock Market Treads Water; Earnings Drive BitAuto
at Investor's Business Daily - Fri Nov 14, 3:21PM CST
Stocks struggled for direction for most of the day Friday amid upbeat data on retail sales and consumer sentiment. But the main indexes ultimately ended mildly higher. The Nasdaq edged up 0.2%, thanks to strength in software and solar issues. But...
NTES: 100.42 (-0.22), ILMN: 182.21 (+1.71), BITA: 89.00 (-2.91), CELG: 105.00 (+0.95)

Synageva Up on New Phase III Data on Sebelipase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:40PM CST
Synageva BioPharma Corp. (GEVA) announced the presentation of new data from a phase III study on sebelipase alfa for LAL deficiency.
GEVA: 77.82 (+2.56), AKRX: 38.94 (+0.73), ADHD: 3.45 (-0.21), CELG: 105.00 (+0.95)

Stocks Drift Lower As Biotechs Tumble
at Investor's Business Daily - Fri Nov 14, 1:48PM CST
Stocks drifted mostly lower Friday with a little more than one hour left in the session, with medical stocks leading the way down. Volume in the stock market today was running lighter than Thursday's levels. The Nasdaq rose less than 0.1%, the S&P...
BIIB: 306.53 (+1.10), NTES: 100.42 (-0.22), HAL: 50.81 (-4.27), BITA: 89.00 (-2.91), BHI: 67.00 (+7.11), CELG: 105.00 (+0.95)

Stocks Mixed; Amazon Jumps On Book Deal
at Investor's Business Daily - Fri Nov 14, 12:32PM CST
Stocks were mixed, but gained a small amount of ground in afternoon trading Friday. A better-than-expected retail sales report lifted Wall Street spirits in the stock market today. The Nasdaq gained 0.1%; the Dow Jones industrial average dropped...
BIIB: 306.53 (+1.10), AMZN: 320.27 (-7.55), HAL: 50.81 (-4.27), ILMN: 182.21 (+1.71), BITA: 89.00 (-2.91), BHI: 67.00 (+7.11), CELG: 105.00 (+0.95)

Midday Glance: Biotechnology companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 101.07 (-0.99), AMGN: 159.34 (+1.66), CELG: 105.00 (+0.95)

Stocks Flat While Medical Issues Tumble
at Investor's Business Daily - Fri Nov 14, 11:04AM CST
Stocks were mixed and mostly unchanged going into the lunch hour Friday after a slightly-better-than-expected retail sales report lifted optimism in the stock market today. The Nasdaq rose 0.1%, while the S&P 500 and the Dow Jones industrial average...
SINA: 39.07 (-0.73), WB: 18.87 (-0.06), TUBE: 15.67 (-1.28), BITA: 89.00 (-2.91), CELG: 104.98 (+0.93)

Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST

BIIB: 306.53 (+1.10), VRTX: 111.98 (+0.64), GILD: 101.07 (-0.99), ALXN: 189.14 (+0.38), AMGN: 159.34 (+1.66), IBB: 291.28 (+3.11), REGN: 406.69 (+11.49), CELG: 104.98 (+0.93)

Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene
PR Newswire - Fri Nov 14, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), iBio Inc. (NYSE MKT: IBIO), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, November 13, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,652.79, up 0.23% and the NASDAQ Composite closed at 4,680.14, up 0.11%. The S&P 500 finished the session 0.05% higher at 2,039.33. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.78, down 0.10%, whereas the index has gained 10.85% in the previous three months. Register for your complimentary reports on these five stocks at:
GILD: 101.07 (-0.99), IBIO: 1.11 (+0.06), ARIA: 6.06 (-0.09), MNKD: 6.17 (+0.01), CELG: 104.98 (+0.93)

Sarepta Initiates Dosing for Study Evaluating Eteplirsen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:40PM CST
Sarepta (SRPT) announced that it has enrolled the first patient in an open label study on eteplirsen in non-ambulant Duchenne muscular dystrophy patients.
RNA: 11.32 (+0.05), SRPT: 15.23 (-0.09), ILMN: 182.20 (+1.70), CELG: 104.98 (+0.93)

Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:00PM CST
Ligand Pharma (LGND) announced the submission of a Marketing Authorisation Application to the European Medicines Agency by its partner GlaxoSmithKline for Revolade.
LGND: 57.78 (-0.01), ILMN: 182.10 (+1.60), GSK: 45.90 (+0.16), CELG: 104.98 (+0.93)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 1

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 2

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 6

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 3

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 5

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 4

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 3

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 3

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading

Top 5 Most Recently Viewed Articles

Recent Developments in Consumer Technology and Trade Relations

Updated Category News Views 245

U.S.-China Trade Dynamics Chinese President Xi Jinping has emphasized ongoing developments in the trade relations between the U.S. and China. In a recent communication with President Donald Trump, both leaders discussed potential measures that could foster a positive trajectory for trade negotiations. Amid these discussions, reports surfaced that the U.S. is contemplating...

Continue Reading
HealthEquity Amid Allegations: An Investor's Guide to HQY

Updated Category News Views 244

Understanding the Investigation into HealthEquity, Inc. Pomerantz LLP is currently conducting a thorough investigation into the claims made by investors of HealthEquity, Inc. This action highlights potential concerns regarding the company’s business practices and the conduct of certain officers and directors. What Triggered the Investigation? The investigation centers...

Continue Reading
PetVivo AI Unveils Innovative Platform to Cut Client Costs

Updated Category News Views 147

Revolutionizing Veterinary Practices with AI PetVivo AI, Inc. is taking the veterinary world by storm with the introduction of PetVivo.ai, an innovative artificial intelligence platform aimed at transforming the pet care sector. With the pet care industry experiencing exponential growth—surpassing $150 billion—this platform promises to decrease client acquisition...

Continue Reading
Avery Dennison's Earnings Anticipation: What Investors Should Know

Updated Category News Views 126

Upcoming Earnings Report for Avery Dennison Avery Dennison (NYSE: AVY) is gearing up for a significant quarter, with expectations heightened ahead of its earnings announcement. Investors are eagerly awaiting the results, which could reveal crucial insights into the company's current performance and future direction. Analysts' Expectations Market analysts predict that...

Continue Reading
Understanding Recent Trends in HDFC Bank Ltd's Short Interest

Updated Category News Views 169

Recent Developments in HDFC Bank Ltd's Short Interest HDFC Bank Ltd (NYSE:HDB) has recently experienced a notable shift in its short interest. According to the latest information, short interest as a percentage of float has decreased by 3.23%. Currently, there are 15.25 million shares sold short, representing 0.3% of the available regular shares for trading. This change...

Continue Reading